BTIG analyst Robert Hazlett raised the firm’s price target on Axsome Therapeutics to $98 from $62 and keeps a Buy rating on the shares. The analyst cites the company’s recently announced positive results in a Phase 3 randomized-withdrawal, placebo-controlled trial called ACCORD, which examines its approved depression therapy AXS-05 in the setting of patients with Alzheimer’s Disease agitation. Hazlett adds that while full data was not disclosed, and timing of the potential approval in the Alzheimer’s agitation indication remains uncertain, he views the ACCORD results as "highly positive" and supportive of the consideration of AXS-05 in the Alzheimer’s agitation setting.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AXSM:
- AXSOME call volume above normal and directionally bullish
- Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY
- Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics price target raised to $86 from $73 at Morgan Stanley